Inducing a broadly neutralizing antibody (bnAb) response is a key goal of HIV-1 vaccine development. Despite significant progress, it is unknown whether vaccine-primed B cells can be reactivated and matured to secrete bona fide bnAbs. In the IAVI C107/C110 single-arm, open-label human trial, VRC01-class memory B cells...
T. Caniels, Madhu S. Prabhakaran, S. Agrawal et al.· bioRxiv· 0 citations
CD4 + T cell responses are an independent correlate of COVID-19 risk among PWH with pre-existing SARS-CoV-2 immunity, and in people with HIV and hybrid immunity, CD4 + T cell responses at one month post-vaccination correlate inversely with risk of COVID-19 over 6 months.
Sharon Khuzwayo, Bo Zhang, Valentin Voillet et al.· Nature Communications· 1 citation
It is demonstrated that prophylactic VRC01 can select for viral escape after infection, underscoring the need for next-generation bnAbs with improved breadth and potency to enhance durability and efficacy of antibody-based HIV prevention.
Carolyn Williamson, Lyle Curry, N. Mkhize et al.· Nature Microbiology· 1 citation
This work shows that persistent germinal centers (GCs) support continued affinity maturation of founder clones and ipsilateral boosting preferentially engages these lineages in secondary GCs, and identifies disfavored mutational trajectories within the V3-glycan bnAb lineage, revealing intrinsic constraints on bnAb lin...
John S. Barber, K. Tonouchi, Chen-Hao Yeh et al.· bioRxiv· 0 citations
Ex vivo, ΔV1 gp120 reduced CCR5 expression on CD4+ T cells relative to WT gp120, consistent with the anti-inflammatory mucosal response by ΔV1-vaccine regimens in vivo, promotes an anti-inflammatory mucosal landscape less permissive to HIV seeding and dissemination following virus exposure.
Isabela Silva de Castro, Mohammad Arif Rahman, Massimiliano Bissa et al.· Cell Reports Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.